公开(公告)号：WO2008154241A1

公开(公告)日：2008-12-18

申请号：PCT/US2008/065727

申请日：2008-06-04

Applicant: ABBOTT LABORATORIES ,  AKRITOPOULOU-ZANZE, Irini ,  WAKEFIELD, Brian D ,  MACK, Helmut ,  TURNER, Sean C ,  GASIECKI, Alan F ,  GRACIAS, Vijaya J ,  SARRIS, Kathy ,  KALVIN, Douglas M ,  MICHMERHUIZEN, Melissa J ,  SHUAI, Qi ,  PATEL, Jyoti R ,  BAKKER, Margaretha ,  TEUSCH, Nicole ,  JOHNSON, Eric T ,  KOVAR, Peter J ,  DJURIC, Stevan W ,  LONG, Andrew J ,  VASUDEVAN, Anil ,  HOBSON, Adrian ,  ST. JOHN MOORE, Nigel ,  WANG, Lu ,  GEORGE, Dawn ,  LI, Biqin ,  FRANK, Kristine

Inventor： AKRITOPOULOU-ZANZE, Irini ,  WAKEFIELD, Brian D ,  MACK, Helmut ,  TURNER, Sean C ,  GASIECKI, Alan F ,  GRACIAS, Vijaya J ,  SARRIS, Kathy ,  KALVIN, Douglas M ,  MICHMERHUIZEN, Melissa J ,  SHUAI, Qi ,  PATEL, Jyoti R ,  BAKKER, Margaretha ,  TEUSCH, Nicole ,  JOHNSON, Eric T ,  KOVAR, Peter J ,  DJURIC, Stevan W ,  LONG, Andrew J ,  VASUDEVAN, Anil ,  HOBSON, Adrian ,  ST. JOHN MOORE, Nigel ,  WANG, Lu ,  GEORGE, Dawn ,  LI, Biqin ,  FRANK, Kristine

IPC: C07D403/04 ,  C07D413/04 ,  C07D417/04

CPC classification number: C07D403/04 ,  C07D413/04 ,  C07D417/04

Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R 1 , R 2 , R 3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.

Abstract translation: 本发明涉及式（I）化合物或其药学上可接受的盐，其中A，R 1，R 2，R 3和m在说明书中定义。 本发明还涉及制备所述化合物的方法和含有所述化合物的组合物，其可用于抑制激酶如糖原合酶激酶3（GSK-3），Rho激酶（ROCK），Janus激酶（JAK），AKT，PAK4 ，PLK，CK2，KDR，MK2，JNK1，极光，pim1和nek2。

公开(公告)号：WO2008060621A3

公开(公告)日：2008-05-22

申请号：PCT/US2007/024076

申请日：2007-11-16

Applicant: ABBOTT LABORATORIES ,  GEORGE, Dawn M. ,  DIXON, Richard W. ,  FRIEDMAN, Michael ,  HOBSON, Adrian ,  LI, Biqin ,  WANG, Lu ,  WU, Xiaoyun ,  WISHART, Neil

Inventor： GEORGE, Dawn M. ,  DIXON, Richard W. ,  FRIEDMAN, Michael ,  HOBSON, Adrian ,  LI, Biqin ,  WANG, Lu ,  WU, Xiaoyun ,  WISHART, Neil

IPC: A61K31/445 ,  C07D211/00

Abstract: The present invention is directed to novel aminopyrrolidines of formula (I), pharmaceutically acceptable salts thereof, metabolites thereof, isomers thereof, stereoisomers thereof or pro-drugs thereof, wherein the variables are as defined herein. The compounds of formula (I) are useful as chemokine receptor antagonists and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.

公开(公告)号：EP2167491A1

公开(公告)日：2010-03-31

申请号：EP08770094.4

申请日：2008-06-04

Applicant: Abbott Laboratories ,  Abbott GmbH & Co. KG

Inventor： AKRITOPOULOU-ZANZE, Irini ,  WAKEFIELD, Brian D ,  MACK, Helmut ,  TURNER, Sean C ,  GASIECKI, Alan F ,  GRACIAS, Vijaya J ,  SARRIS, Kathy ,  KALVIN, Douglas M ,  MICHMERHUIZEN, Melissa J ,  SHUAI, Qi ,  PATEL, Jyoti R ,  BAKKER, Margaretha ,  TEUSCH, Nicole ,  JOHNSON, Eric F. ,  KOVAR, Peter J ,  DJURIC, Stevan W ,  LONG, Andrew J ,  VASUDEVAN, Anil ,  HOBSON, Adrian ,  ST. JOHN MOORE, Nigel ,  WANG, Lu ,  GEORGE, Dawn ,  LI, Biqin ,  FRANK, Kristine

IPC: C07D403/04 ,  C07D413/04 ,  C07D417/04

CPC classification number: C07D403/04 ,  C07D413/04 ,  C07D417/04

Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R1, R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.

公开(公告)号：EP2099454A2

公开(公告)日：2009-09-16

申请号：EP07867491.8

申请日：2007-11-16

Applicant: ABBOTT LABORATORIES

Inventor： GEORGE, Dawn M. ,  DIXON, Richard W. ,  FRIEDMAN, Michael ,  HOBSON, Adrian ,  LI, Biqin ,  WANG, Lu ,  WU, Xiaoyun ,  WISHART, Neil

IPC: A61K31/445 ,  C07D211/00

CPC classification number: A61K31/454 ,  A61K31/437 ,  A61K31/438 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4747 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/553 ,  C07D207/14 ,  C07D401/04 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/10 ,  C07D487/14

Abstract: The present invention is directed to novel aminopyrrolidines of formula (I), pharmaceutically acceptable salts thereof, metabolites thereof, isomers thereof, stereoisomers thereof or pro-drugs thereof, wherein the variables are as defined herein. The compounds of formula (I) are useful as chemokine receptor antagonists and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.